ArticleMolecular neurobiology2025
Tau Protein Disrupts Mitochondrial Homeostasis in a Yeast Model: Implications for Alzheimer's Disease.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Vitamin B6 Modifies Tau-Induced Cellular Stress- and Proteostasis-Related Responses.Journal of fungi (Basel, Switzerland) · 2026Article
- Decoding the Metabolic Signatures of Neurodegeneration Diseases: Advances in Mass Spectrometry-Based Metabolomics.Metabolites · 2026Review
- Retrograde signaling is required for Slm35-mediated negative regulation of mitophagy in yeast.Biology open · 2026Article
- Tau-Mitochondria Interactions in Neurodegeneration: Mechanisms and Therapeutic Potential.Cellular and molecular neurobiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The microtubule-associated protein tau plays a central role in neurodegenerative diseases, called tauopathies, but the mechanism involved remains incompletely understood. Here, we used Saccharomyces cerevisiae as a model system to investigate the consequences of expressing the shortest human tau isoform 0N3R. After transfected, we detected widespread cellular distribution of tau and phosphorylation at key pathological residues involved in Alzheimer's disease (Ser199/202). We also found that a portion of tau localizes within the mitochondrial matrix. The mitochondrial uptake of tau required a chaperone machinery, including Hsp104 and the Ssa1/Ydj1 bichaperone complex. Functionally, tau expression caused marked mitochondrial fragmentation, reduced oxygen consumption, and a decrease in membrane potential during stationary phase, indicating impaired mitochondrial function. This dysfunction activated the yeast retrograde signaling pathway. Importantly, tau expression enhanced mitochondrial clearance through mitophagy, both under nitrogen starvation and during stationary phase, and this effect was dependent on the retrograde response. Together, these findings demonstrate that tau expression in yeast perturbs mitochondrial homeostasis, triggering both compensatory nuclear signaling and increased mitochondrial turnover, adding evidence on the potential mechanisms involved in tau neurotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.